Subsequently, we explored the use of ICB namely, single agent anti-PD-1 and anti-CTLA-4 therapy to determine if these agents might enhance anti-tumour Th1 immunity post-operatively using our ex vivo PBMC expansion protocol (Figure 3A). This evidence concerns the gene CTLA4 and neoplasm.